Related Experiment Videos
Interferon gamma in trauma-related infections
1Department of Surgery, Loyola University Medical Center, Maywood, IL 60153, USA.
Intensive Care Medicine
|October 1, 1996
Summary
Interferon gamma therapy showed a trend toward reducing deaths from major infections in trauma patients. However, results were influenced by one high-enrolling center, warranting further investigation.
Area of Science:
- Trauma care
- Infectious disease management
- Immunotherapy
Background:
- Major injury patients are at high risk for infections.
- Interferon gamma is an immunomodulatory cytokine with potential anti-infective properties.
Purpose of the Study:
- To evaluate the efficacy of interferon gamma in reducing infection rates and improving outcomes in patients with major injuries.
- To assess the impact of interferon gamma on infection-related mortality in severe trauma.
Main Methods:
- Randomized, double-blind, placebo-controlled trial conducted across nine US trauma centers.
- Four hundred sixteen patients with severe injury (ISS ≥ 25 or ISS ≥ 20 with wound contamination) were enrolled.
- Intervention involved daily subcutaneous recombinant human interferon gamma (100 ug) or placebo for up to 21 days, alongside standard antibiotics.
Main Results:
- Infection rates (major and minor) were comparable between interferon gamma and placebo groups.
- A lower mortality rate related to major infection was observed in the interferon gamma group (3% vs 9%).
- Results were significantly influenced by one center with high enrollment and infection/death rates.
Conclusions:
- Interferon gamma therapy demonstrated a potential benefit in reducing infection-related deaths in major trauma patients.
- Further research is necessary to confirm these findings and clarify the role of interferon gamma in managing severe infections.
- The impact of study site variability on outcomes requires consideration in future trials.